Stay updated with breaking news from Universal Immunisation Programme. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Through this collaboration, Bharat Biotech and Bilthoven Biologicals (BBio) will jointly obtain regulatory approvals and licences required to commercially manufacture oral polio vaccines (OPVs) in India for global supplies from drug substances manufactured in the Netherlands at BBio.
Hyderabad: Vaccine maker Bharat Biotech and Bilthoven Biologicals BV (BBio), a wholly owned subsidiary of Serum Institute of India Private Limited, based in the Netherlands, announced a collaboration...
Through this collaboration, Bharat Biotech and Bilthoven Biologicals will jointly obtain regulatory approvals and licences required to commercially manufacture OPVs in India for global supplies.
The two biotech companies have signed a requisite agreement wherein Bharat Biotech will procure drug substances for the production of oral polio vaccines to be supplied within India and globally. Both companies will jointly obtain the regulatory approvals and licenses required to commercially manufacture OPVs in India for global supplies from drug substances manufactured in the Netherlands at Bilthoven Biologicals.
Collaboration aims at enhancing production and security of supply for Oral Polio Vaccines OPV